The Scientist : High-Priced Biotech Drugs: Are They Worth It? [6/12/2004]

High-Priced Biotech Drugs: Are They Worth It?

Insurers mull the question, and the answer could affect biotech drug development

Email: Susan Warner - swarner@the-scientist.com
The Scientist 2004, 18(23):42

6 December 2004

Visudyne, a drug for macular degeneration, costs $2,500–4,000 for a course of treatment. Zevalin and Bexxar, used for non-Hodgkins lymphoma, can cost more than $20,000 per dose. While all these drugs can help certain patients, reimbursement has been a problem and some insurers have refused to pay.

Password

> Forgot Password?
> FAQ
> Subscribe

Subscribing to The Scientist is easy and inexpensive.

And you can choose from many options. Try us out with an online day pass starting at only $4.95. Or, get it all with unlimited online access to The Scientist Archive and door-to-door delivery of our monthly print magazine.


	The Scientist also offers site licenses to institutions and organizations. When your librarian adds The Scientist to the library's collection, you can get unlimited online access through your place of work or study. Recommend The Scientist today